Psychological complications in patients with acromegaly: relationships with sex, arthropathy, and quality of life.
Acromegaly
Anxiety
Articular function
Depression
QoL
Radiotherapy
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
29
03
2022
accepted:
02
06
2022
pubmed:
3
7
2022
medline:
20
8
2022
entrez:
2
7
2022
Statut:
ppublish
Résumé
Current treatment of acromegaly restores a normal life expectancy in most cases. So, the study of persistent complications affecting patients' quality of life (QoL) is of paramount importance, especially motor disability and depression. In a large cohort of acromegalic patients we aimed at establishing the prevalence of depression, to look for clinical and sociodemographic factors associated with it, and to investigate the respective roles (and interactions) of depression and arthropathy in influencing QoL. One hundred and seventy-one acromegalic patients (95 women and 76 men, aged 20-85 years) among those recruited in a cross-sectional Italian multicentric study were investigated. Each patient filled in three validated questionnaires: AcroQoL, WOMAC (measuring articular pain, stiffness and functionality), and AIMS (evaluating articular symptoms and depression). A very high (up to 28%) depression rate was detected in acromegalic subjects. Two patients showing pathological AIMS depression scores, committed suicide during the three years observational period. In our population poor psychological status was significantly associated with female sex. Furthermore, a significant strong correlation was found between AIMS depression score and WOMAC score. Both depression and arthropathy-related motor disability turned out to independently contribute with similar strength to the impairment of QoL. We report a high prevalence of depression in acromegaly, which is associated with female sex and arthropathy. Both depression and arthropathy strongly and independently contribute to the impaired QoL of patients. Our study shows that assessment and monitoring of psychological status is mandatory in acromegaly, also suggesting an inexpensive tool for this assessment.
Identifiants
pubmed: 35779206
doi: 10.1007/s12020-022-03106-8
pii: 10.1007/s12020-022-03106-8
pmc: PMC9385810
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
510-518Investigateurs
Francesco Cavagnini
(F)
Diego Ferone
(D)
Sabrina Corbetta
(S)
Luigi Bartalena
(L)
Paolo Beck Peccoz
(PB)
Maura Arosio
(M)
Andrea Lania
(A)
Annamaria Colao
(A)
Rosario Pivonello
(R)
Ettore Degli Uberti
(ED)
Ezio Ghigo
(E)
Andrea Giustina
(A)
Enio Martino
(E)
Alfredo Pontecorvi
(A)
Nicola Sicolo
(N)
Francesco Trimarchi
(F)
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022. The Author(s).
Références
A. Colao, L.F.S. Grasso, A. Giustina, et al. Acromegaly. Nat. Rev. Dis. Prim. 5 (2019)
S. Melmed, Acromegaly pathogenesis and treatment. J. Clin. Invest. 119, 3189–3202 (2009)
doi: 10.1172/JCI39375
E. Ritvonen, E. Löyttyniemi, P. Jaatinen et al. Mortality in acromegaly: a 20-year follow-up study. Endocr. Relat. Cancer. 23, 469–480 (2016)
doi: 10.1530/ERC-16-0106
L.M. Fatti, B. Cangiano, G.Vitale et al. Arthropathy in acromegaly: a questionnaire-based estimation of motor disability and its relation with quality of life and work productivity. Pituitary. https://doi.org/10.1007/s11102-019-00966-8 (2019)
M. Kołtowska-Häggsträm, C. Menzel, C. Strasburger et al. Predictors of Quality of Life in 165 Patients With Acromegaly: Results From a Single-Center Study. Endocr. Pract. 23, 79–88 https://doi.org/10.4158/ep161373.or (2016)
C. Sievers, C. Dimopoulou, H. Pfister et al. Prevalence of mental disorders in acromegaly: a cross-sectional study in 81 acromegalic patients. Clin. Endocrinol.(Oxf) 71, 691–701 (2009)
doi: 10.1111/j.1365-2265.2009.03555.x
D.M. Szczesniak, A. Jawiarczyk-Przybylowska, L. Matusiak et al. Is there any difference in acromegaly and other chronic disease in quality of life and psychiatric morbidity? Endokrynol. Pol. 68, 524–532 (2017)
pubmed: 28879648
E. Karathanasi, M. Poulasouchidou, D. Selalmatzidou et al. Psychological profile and quality of life in patients with acromegaly in Greece. Is there any difference with other chronic diseases? Endocrine 47, 564–571 (2014)
doi: 10.1007/s12020-014-0166-5
C. Dimopoulou, S.M. Leistner, M. Ising et al. Body Image Perception in Acromegaly Is Not Associated with Objective Acromegalic Changes but Depends on Depressive Symptoms. Neuroendocrinology 105, 115–122 (2017)
doi: 10.1159/000448519
J. Tiemensma, A.M. Pereira, J.A. Romijn et al. Persistent negative illness perceptions despite long-term biochemical control of acromegaly: Novel application of the drawing test. Eur. J. Endocrinol. 172, 583–593 (2015)
doi: 10.1530/EJE-14-0996
P. Pantanetti, N. Sonino, G. Arnaldi, M. Boscaro, Self Image and Quality of Life in Acromegaly. Pituitary 5, 17–19 (2002)
doi: 10.1023/A:1022145116901
C. Sievers, M. Ising, H. Pfister et al. Personality in patients with pituitary adenomas is characterized by increased anxiety-related traits: comparison of 70 acromegalic patients with patients with non-functioning pituitary adenomas and age- and gender-matched controls. Eur. J. Endocrinol. 160, 367–373 (2009)
doi: 10.1530/EJE-08-0896
V.J. Geraedts, C. Dimopoulou, M. Auer et al. Health outcomes in acromegaly: Depression and anxiety are promising targets for improving reduced quality of life. Front Endocrinol. 5, 1–7 (2014)
S.M. Webb, L. Prieto, X. Badia et al. Acromegaly Quality of Life Questionnaire (ACROQOL) a new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties. Clin. Endocrinol. 57, 251–258 (2002)
doi: 10.1046/j.1365-2265.2002.01597.x
P.J. Trainer, W.M. Drake, L. Katznelson et al. Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist Pegvisomant. N. Engl. J. Med. 342, 1171–1177 (2000)
doi: 10.1056/NEJM200004203421604
S.J.C.M.M. Neggers, M.O. Van Aken, W.W. De Herder et al. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J. Clin. Endocrinol. Metab. 93, 3853–3859 (2008)
doi: 10.1210/jc.2008-0669
N. Bellamy, W.W. Buchanan, C.H. Goldsmith et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J. Rheumatol. 15, 1833–1840 (1988)
pubmed: 3068365
F. Salaffi, G. Leardini, B. Canesi et al. Reliability and validity of the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index in Italian patients with osteoarthritis of the knee. Osteoarthr. Cartil. 11, 551–560 (2003)
doi: 10.1016/S1063-4584(03)00089-X
R.F. Meenan, P.M. Gertman, J.H. Mason, R. Dunaif, The arthritis impact measurement scales. Further investigations of a health status measure. Arthritis Rheum. 25, 1048–1053 (1982)
doi: 10.1002/art.1780250903
F. Cavalieri, F. Salaffi, G.F. Ferraccioli, Relationship between physical impairment, psychological variables and pain in rheumatoid disability. An analysis of their relative impact. Clin. Exp. Rheumatol. 9, 47–50 (1991)
pubmed: 2054967
D.J. Hawley, F. Wolfe, Depression is not more common in rheumatoid arthritis: a 10-year longitudinal study of 6,153 patients with rheumatic disease. J. Rheumatol. 20, 2025–2031 (1993)
pubmed: 8014929
C. Chuang-Stein, Summarizing Laboratory Data with Different Reference Ranges in Multi-Center Clinical Trials. Drug Inf. J. 26, 77–84 (1992)
doi: 10.1177/009286159202600108
M. Tenuta, F. Carlomagno, B. Cangiano et al. Somatotropic-Testicular Axis: A crosstalk between GH/IGF-I and gonadal hormones during development, transition, and adult age. Andrology https://doi.org/10.1111/andr.12918 (2020)
W.R. van Furth, G.K. Stalla, C. Sievers et al. Predictors of Quality of Life in Acromegaly: No Consensus on Biochemical Parameters. Front Endocrinol. 8, 1–14 (2017)
S. Frara, M.M. Uygur, L. di Filippo et al. High Prevalence of Vertebral Fractures Associated with Preoperative GH Levels in Patients with recent Diagnosis of Acromegaly. J. Clin. Endocrinol. Metab. https://doi.org/10.1210/CLINEM/DGAC183 (2022)
L.S. Kunzler, L.A. Naves, L.A. Casulari, The Effect of Cognitive-Behavioral Therapy on Acromegalics After a 9-Month Follow-Up. Front Endocrinol. 10, 380 (2019)
doi: 10.3389/fendo.2019.00380
L.S. Kunzler, L.A. Naves, L.A. Casulari, Cognitive-behavioral therapy improves the quality of life of patients with acromegaly. Pituitary 21, 323–333 (2018)
doi: 10.1007/s11102-018-0887-1